• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Trending:
  • Kashmir
  • Elections
Saturday, June 6, 2026

Daily Times

Your right to know

  • HOME
  • Latest
  • Iran-Israel war
  • Gilgit Baltistan Election
  • Pakistan
    • Balochistan
    • Gilgit Baltistan
    • Khyber Pakhtunkhwa
    • Punjab
    • Sindh
  • World
  • Editorials & Opinions
    • Editorials
    • Op-Eds
    • Commentary / Insight
    • Perspectives
    • Cartoons
    • Letters to the Editor
    • Featured
    • Blogs
      • Pakistan
      • World
      • Lifestyle
      • Culture
      • Sports
  • Business
  • Sports
  • E-PAPER
    • Lahore
    • Islamabad
    • Karachi

Web Desk

I would’ve settled for vaccines that prevent 70-75% people from contracting coronavirus: Fauci

Published on: November 17, 2020 11:47 AM

Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, said the Moderna vaccine’s early results were “stunningly impressive”.

Anthony Fauci, United States’ top infectious disease expert, says he would have settled for vaccines with a prevention rate of 70-75%.

In an interview with AFP, Fauci said the idea that there is a 94.5% effective vaccine is stunningly impressive. “It is really a spectacular result that I don’t think anybody had anticipated would be this good.”

He add that the findings were an emphatic validation of experimental mRNA technology that some had doubted.

Fauci leads the National Institutes of Allergies and Infectious Diseases (NIAID), which began co-developing the vaccine with the US biotech company in January, shortly after China shared the genetic sequence of the new coronavirus.

How does the vaccine work?

It is based on a relatively new technology that uses a synthetic version of a molecule called “messenger RNA” to hack into human cells, and effectively turn them into vaccine-making factories.

No vaccine based on this platform has ever been approved.

“There were many people who had reservations about using something that had not been tried and true over the years; in fact, some people even criticized us for that,” said Fauci.

On Monday, Moderna and NIAID announced their preliminary results based on 95 of the 30,000 volunteers they had recruited who fell ill with Covid-19.

Of the 95, 90 had been in the trial’s placebo group, and five in the group that received the drug, called mRNA-1273, translating to an efficacy rate of 94.5%.

Fauci recalled that some had questioned whether the vaccine would prevent severe forms of Covid-19, not just mild or moderate cases – and this too had been resoundingly answered.

“There were 11 severe events, none in the vaccine group – 11 in the placebo group, so that settles the question of whether it prevents severe disease, which it definitely does.”

‘The data speak for themselves’

It follows a similarly impressive result from American pharmaceutical firm Pfizer and its German partner BioNTech last week, who reported an efficacy of 90% for their vaccine.

Asked whether it was too early to say if mRNA technology had now been proven, Fauci – who is usually known for his cautious statements – said the jury was definitely in.

“I think when you have two vaccines like this, that have proven to be greater than 90% effective, I think that mRNA is here, it’s established itself, it doesn’t need to prove anything anymore.

“The data speak for themselves; it isn’t me, it isn’t my opinion – look at the data,” he said.

Traditional virus vaccines use actual viruses that have to be grown in chicken eggs or fetal cell lines and then weakened so they don’t harm people – a process that can take many months.

By contrast, the Covid-19 mRNA vaccines deliver the genetic information needed to create a protein that lies on the surface of the virus – called the spike protein – directly to cells in the human body, which then grow it.

This primes the immune system to make antibodies to the actual virus, and has the major advantage of shortening vaccine development time to a matter of weeks, once scientists have the genetic sequence of the protein they want to create.

Fauci was keen to highlight the critical work of NIAID, which he said was responsible for developing a precise way to orient the spike protein molecule such that it elicited the strongest immune response.

Unanswered questions

But there are still some unanswered questions, including how long the immunity lasts.

Fauci said he was ‘certain’ it would endure to some extent, as immune system cells called “memory B cells” remained on standby to generate new antibodies to the virus.

But for how long was unclear. “We don’t know whether it’s going to be a year, two years, three years, five years, we don’t know,” he said.

The vaccine could receive emergency approval in the US within a matter of weeks.

Looking forward, Fauci said he was worried about anti-vaccine sentiment in the United States, the country that has been the worst-hit by the pandemic.

“You’ve got to overcome that and convince people to get vaccinated, because a vaccine with a high degree of efficacy is of no use if nobody gets vaccinated.”

Filed Under: Health, World Tagged With: Headline

Submit a Comment




Primary Sidebar




Latest News

Alexander Zverev eases past Jakub Mensik in French Open semifinals

Taylor to face Pili in Croke Park farewell

FIFA bans vuvuzelas from World Cup stadiums

France brush off Ivory Coast loss, call it timely World Cup reminder

Legendary boxer Muhammad Ali’s 10th death anniversary observed

Pakistan

JAAC declared proscribed party ahead of AJK polls on July 27

Fixed tax scheme for small retailers launched to raise Rs 50bn annually

Govt cuts petrol price by Rs 4 per litre, keeps diesel’s unchanged

Bilawal promises GB voters with land and job rights

Iran declares support for Hezbollah with wider peace deal in doubt

More Posts from this Category

Business

SBP’s ‘Go Cashless’ campaign saw Rs 34bn in digital transactions on Eid

Short-term inflation down by 0.56%

Saudi-Pak Business Council shows interest in infrastructure investment

‘Govt, allies united in efforts to craft people-centric budget’

Rupee records gain against US dollar

More Posts from this Category

World

CENTCOM space post signals wider US military footprint

US official delivers Trump’s “good hello” to Putin

NASA lifts ISS evacuation alert after leak

More Posts from this Category




Footer

Home
Lead Stories
Latest News
Editor’s Picks

Culture
Life & Style
Featured
Videos

Editorials
OP-EDS
Commentary
Advertise

Cartoons
Letters
Blogs
Privacy Policy

Contact
Company’s Financials
Investor Information
Terms & Conditions

Facebook
Twitter
Instagram
Youtube

© 2026 Daily Times. All rights reserved.

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.